Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies

Journal of Immunological Methods

Volumn 424, Issue , 2015, Pages 64-79

  Hallé, Maxime ^a,c   Tribout Jover, Pascale ^a   Lanteigne, Anne Marie ^a   Boulais, Jonathan ^a   St Jean, Julien R ^a   Jodoin, Rachel ^a   Girouard, Marie Pier ^a   Constantin, Florin ^a   Migneault, Annik ^a   Renaud, Frédéric ^b   Didierlaurent, Arnaud M ^b   Mallett, Corey P ^a   Burkhart, David ^d   Pilorget, Anthony ^a   Palmantier, Rémi ^b   Larocque, Daniel ^a  

^a GLAXOSMITHKLINE   (Canada)

^b GSK   (Belgium)

^c Université Laval   (Canada)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adjuvant; Alzheimer's disease; Amyloid beta; A uptake; Monocyte; Phagocytosis; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; IMMUNOLOGICAL ADJUVANT; INSULINASE; MONOCLONAL ANTIBODY; PHOSPHORYL LIPID A; PRESENILIN 1; TOLL LIKE RECEPTOR 4; ACTIN; ADJUVANT SYSTEM 01; DRUG COMBINATION; LIPID A; SAPONIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; IMMUNOTHERAPY; IN VIVO STUDY; INTERNALIZATION; METHODOLOGY; MONITORING; MONOCYTE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; VACCINATION; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BRAIN; CELL LINE; DISEASE MODEL; DRUG COMBINATION; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION; TRANSGENIC MOUSE;

MURINAE; MUS;

ACTINS; ADJUVANTS, IMMUNOLOGIC; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CELL LINE; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LIPID A; MICE; MICE, TRANSGENIC; MONOCYTES; PHAGOCYTOSIS; PROTEIN MULTIMERIZATION; PROTEOLYSIS; SAPONINS; VACCINATION;

EID: 84940462477     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.05.002     Document Type: Article

References (85)

1. Ackerman M.E., Moldt B., Wyatt R.T., Dugast A.S., McAndrew E., Tsoukas S., Jost S., Berger C.T., Sciaranghella G., Liu Q., Irvine D.J., Burton D.R., Alter G. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 2011, 366:8.
2. Arai H., Suzuki H., Yoshiyama T. Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies. Curr. Alzheimer Res. 2015, 12:242.
3. Arendash G.W., Gordon M.N., Diamond D.M., Austin L.A., Hatcher J.M., Jantzen P., DiCarlo G., Wilcock D., Morgan D. Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol. 2001, 20:737.
4. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M.L., Volpe S., Ratto S., Dagna-Bricarelli F., Baldo C., Argusti A., Odetti P., Piccini A., Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004, 63:828.
5. Avagyan H., Goldenson B., Tse E., Masoumi A., Porter V., Wiedau-Pazos M., Sayre J., Ong R., Mahanian M., Koo P., Bae S., Micic M., Liu P.T., Rosenthal M.J., Fiala M. Immune blood biomarkers of Alzheimer disease patients. J. Neuroimmunol. 2009, 210:67.
6. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., Hyman B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 2001, 7:369.
7. Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., Morley J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002, 23:2223.
8. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916.
9. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2023.
10. Barten D.M., Guss V.L., Corsa J.A., Loo A., Hansel S.B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B.J., Polson C.T., Wang J., Roberts S.B., Hendrick J.P., Anderson J.J., Loy J.K., Denton R., Verdoorn T.A., Smith D.W., Felsenstein K.M. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J. Pharmacol. Exp. Ther. 2005, 312:635.
11. Blennow K., Zetterberg H., Fagan A.M. Fluid biomarkers in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2:a006221.
12. Boissonneault V., Filali M., Lessard M., Relton J., Wong G., Rivest S. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009, 132:1078.
13. Burgess B.L., McIsaac S.A., Naus K.E., Chan J.Y., Tansley G.H., Yang J., Miao F., Ross C.J., van Eck M., Hayden M.R., van Nostrand W., St George-Hyslop P., Westaway D., Wellington C.L. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol. Dis. 2006, 24:114.
14. Chabot S.M., Chernin T.S., Shawi M., Wagner J., Farrant S., Burt D.S., Cyr S., Neutra M.R. TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine 2007, 25:5348.
15. Chuang J.Y., Lee C.W., Shih Y.H., Yang T., Yu L., Kuo Y.M. Interactions between amyloid-beta and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. PLoS One 2012, 7:e33120.
16. Clifford P.M., Zarrabi S., Siu G., Kinsler K.J., Kosciuk M.C., Venkataraman V., D'Andrea M.R., Dinsmore S., Nagele R.G. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res. 2007, 1142:223.
17. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13:843.
18. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850.
19. DeMattos R.B., Bales K.R., Cummins D.J., Paul S.M., Holtzman D.M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002, 295:2264.
20. Desjardins M., Griffiths G. Phagocytosis: latex leads the way. Curr. Opin. Cell Biol. 2003, 15:498.
21. Devanand D.P., Schupf N., Stern Y., Parsey R., Pelton G.H., Mehta P., Mayeux R. Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurology 2011, 77:125.
22. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4162.
23. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14:11.
24. Fiala M., Lin J., Ringman J., Kermani-Arab V., Tsao G., Patel A., Lossinsky A.S., Graves M.C., Gustavson A., Sayre J., Sofroni E., Suarez T., Chiappelli F., Bernard G. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 2005, 7:221.
25. Frenkel D., Puckett L., Petrovic S., Xia W., Chen G., Vega J., Dembinsky-Vaknin A., Shen J., Plante M., Burt D.S., Weiner H.L. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann. Neurol. 2008, 63:591.
26. Games D., Bard F., Grajeda H., Guido T., Khan K., Soriano F., Vasquez N., Wehner N., Johnson-Wood K., Yednock T., Seubert P., Schenk D. Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42. Ann. N. Y. Acad. Sci. 2000, 920:274.
27. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553.
28. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101.
29. Hallé M., Gomez M.A., Stuible M., Shimizu H., McMaster W.R., Olivier M., Tremblay M.L. The Leishmania surface protease GP63 cleaves multiple intracellular proteins and actively participates in p38 mitogen-activated protein kinase inactivation. J. Biol. Chem. 2009, 284:6893.
30. Herber D.L., Roth L.M., Wilson D., Wilson N., Mason J.E., Morgan D., Gordon M.N. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp. Neurol. 2004, 190:245.
31. Herber D.L., Mercer M., Roth L.M., Symmonds K., Maloney J., Wilson N., Freeman M.J., Morgan D., Gordon M.N. Microglial activation is required for Abeta clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J. Neuroimmune Pharmacol. 2007, 2:222.
32. Hjorth E., Frenkel D., Weiner H., Schultzberg M. Effects of immunomodulatory substances on phagocytosis of abeta(1-42) by human microglia. Int. J. Alzheimers Dis. 2010, 2010.
33. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216.
34. Holtzman D.M. Alzheimer's disease: moving towards a vaccine. Nature 2008, 454:418.
35. Howlett D.R., Richardson J.C., Austin A., Parsons A.A., Bate S.T., Davies D.C., Gonzalez M.I. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 2004, 1017:130.
36. Innocenti M., Salvietti E., Guidotti M., Casini A., Bellandi S., Foresti M.L., Gabbiani C., Pozzi A., Zatta P., Messori L. Trace copper(II) or zinc(II) ions drastically modify the aggregation behavior of amyloid-beta1-42: an AFM study. J. Alzheimers Dis. 2010, 19:1323.
37. Jensen M.T., Mottin M.D., Cracchiolo J.R., Leighty R.E., Arendash G.W. Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience 2005, 130:667.
38. Jonsson T., Atwal J.K., Steinberg S., Snaedal J., Jonsson P.V., Bjornsson S., Stefansson H., Sulem P., Gudbjartsson D., Maloney J., Hoyte K., Gustafson A., Liu Y., Lu Y., Bhangale T., Graham R.R., Huttenlocher J., Bjornsdottir G., Andreassen O.A., Jonsson E.G., Palotie A., Behrens T.W., Magnusson O.T., Kong A., Thorsteinsdottir U., Watts R.J., Stefansson K. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96.
39. Kuo Y.M., Emmerling M.R., Lampert H.C., Hempelman S.R., Kokjohn T.A., Woods A.S., Cotter R.J., Roher A.E. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 1999, 257:787.
40. Liu S., Breitbart A., Sun Y., Mehta P.D., Boutajangout A., Scholtzova H., Wisniewski T. Blocking the apolipoprotein E/amyloid beta interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid beta and tau pathology. J. Neurochem. 2014, 128:577.
41. Maier M., Seabrook T.J., Lazo N.D., Jiang L., Das P., Janus C., Lemere C.A. Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J. Neurosci. 2006, 26:4717.
42. Mandrekar S., Jiang Q., Lee C.Y., Koenigsknecht-Talboo J., Holtzman D.M., Landreth G.E. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J. Neurosci. 2009, 29:4252.
43. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129.
44. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
45. Mayeux R., Tang M.X., Jacobs D.M., Manly J., Bell K., Merchant C., Small S.A., Stern Y., Wisniewski H.M., Mehta P.D. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann. Neurol. 1999, 46:412.
46. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185.
47. Michaud J.P., Hallé M., Lampron A., Theriault P., Prefontaine P., Filali M., Tribout-Jover P., Lanteigne A.M., Jodoin R., Cluff C., Brichard V., Palmantier R., Pilorget A., Larocque D., Rivest S. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:1941.
48. + monocytes only under defined host conditions. Nat. Neurosci. 2007, 10:1544.
49. Miller B.C., Eckman E.A., Sambamurti K., Dobbs N., Chow K.M., Eckman C.B., Hersh L.B., Thiele D.L. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6221.
50. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5048.
51. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 9:448.
52. Noguchi A., Matsumura S., Dezawa M., Tada M., Yanazawa M., Ito A., Akioka M., Kikuchi S., Sato M., Ideno S., Noda M., Fukunari A., Muramatsu S., Itokazu Y., Sato K., Takahashi H., Teplow D.B., Nabeshima Y., Kakita A., Imahori K., Hoshi M. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J. Biol. Chem. 2009, 284:32895.
53. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46.
54. Oyama R., Yamamoto H., Titani K. Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim. Biophys. Acta 2000, 1479:91.
55. Panza F., Logroscino G., Imbimbo B.P., Solfrizzi V. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?. Curr. Opin. Psychiatry 2014, 27:128.
56. Pryor N.E., Moss M.A., Hestekin C.N. Unraveling the early events of amyloid-beta protein (Abeta) aggregation: techniques for the determination of Abeta aggregate size. Int. J. Mol. Sci. 2012, 13:3038.
57. Quintanilla R.A., Orellana J.A., von Bernhardi R. Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch. Med. Res. 2012, 43:632.
58. Rafii M.S., Aisen P.S. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
59. Richard K.L., Filali M., Prefontaine P., Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28:5784.
60. Richardson J.C., Kendal C.E., Anderson R., Priest F., Gower E., Soden P., Gray R., Topps S., Howlett D.R., Lavender D., Clarke N.J., Barnes J.C., Haworth R., Stewart M.G., Rupniak H.T. Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 2003, 122:213.
61. Roychaudhuri R., Yang M., Hoshi M.M., Teplow D.B. Amyloid beta-protein assembly and Alzheimer disease. J. Biol. Chem. 2009, 284:4749.
62. Schagger H. Tricine-SDS-PAGE. Nat. Protoc. 2006, 1:16.
63. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173.
64. Schupf N., Tang M.X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14052.
65. Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008, 192:106.
66. Serrano-Pozo A., William C.M., Ferrer I., Uro-Coste E., Delisle M.B., Maurage C.A., Hock C., Nitsch R.M., Masliah E., Growdon J.H., Frosch M.P., Hyman B.T. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010, 133:1312.
67. Sgarbossa A. Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int. J. Mol. Sci. 2012, 13:17121.
68. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534.
69. Spires-Jones T.L., Mielke M.L., Rozkalne A., Meyer-Luehmann M., de Calignon A., Bacskai B.J., Schenk D., Hyman B.T. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol. Dis. 2009, 33:213.
70. Sudoh S., Frosch M.P., Wolf B.A. Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 2002, 41:1091.
71. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006.
72. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y., Shoji S. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 1996, 141:65.
73. Tayeb H.O., Murray E.D., Price B.H., Tarazi F.I. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?. Expert. Opin. Biol. Ther. 2013, 13:1075.
74. Thies W., Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9:208.
75. Tiiman A., Palumaa P., Tougu V. The missing link in the amyloid cascade of Alzheimer's disease - metal ions. Neurochem. Int. 2013, 62:367.
76. + T cell responses to amyloid-{beta} peptide in mice through regulatory T cell-mediated inhibition. J. Immunol. 2011, 187:4492.
77. Vellas B., Black R., Thal L.J., Fox N.C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M., Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 2009, 6:144.
78. Weiner H.L., Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 2006, 6:404.
79. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003, 23:3745.
80. Wilcock D.M., Munireddy S.K., Rosenthal A., Ugen K.E., Gordon M.N., Morgan D. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol. Dis. 2004, 15:11.
81. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., Wilson D., Wilson N., Freeman M.J., Gordon M.N., Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24:6144.
82. Wilkinson B., Koenigsknecht-Talboo J., Grommes C., Lee C.Y., Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 2006, 281:20842.
83. Wu C.W., Liao P.C., Yu L., Wang S.T., Chen S.T., Wu C.M., Kuo Y.M. Hemoglobin promotes Abeta oligomer formation and localizes in neurons and amyloid deposits. Neurobiol. Dis. 2004, 17:367.
84. Yan M.H., Wang X., Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic. Biol. Med. 2013, 62:90.
85. Zhang J., Wu X., Qin C., Qi J., Ma S., Zhang H., Kong Q., Chen D., Ba D., He W. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2003, 14:365.